CHICAGO – CARs just keep getting better, with a new target for multiple myeloma.
The addition of rituximab has been shown to increase median survival rates among some patients with non-Hodgkin lymphoma.
MONTREAL – How could ESR change osteomyelitis diagnosis in patients with SCD?
Researchers conducted a prospective evaluation of treatment patterns and outcomes for elderly patients with chronic lymphocytic leukemia in a real...
A newly developed “robust and inexpensive” prognostic tool may allow more tailored therapy for youth with intermediate-risk Hodgkin lymphoma.
Veterans who served ≥ 30 days at Camp Lejeune and developed 1 of 8 cancer types are eligible for VA reimbursement.
Study data reveal pretreatment scanning significantly reduces the risk of relapse and radiation exposure adverse effects in patients with Hodgkin...
Next-generation sequencing might be useful to monitor for minimum residual disease in multiple myeloma.
Researchers explored the connection of low-density lipoproteins and the development of chronic lymphocytic leukemia.
Use of Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of Intravascular Diffuse Large B-Cell Lymphoma
Patients with intravascular large B-cell lymphoma often pose a significant diagnostic challenge, particularly in the early stages of the disease,...